We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Alnylam Initiates Phase I Clinical Study of ALN-VSP in Patients with Liver Cancer

News   Apr 06, 2009

 
Alnylam Initiates Phase I Clinical Study of ALN-VSP in Patients with Liver Cancer
 
 
Advertisement
 

RELATED ARTICLES

Adding Abemaciclib to Hormonal Therapy Reduces Risk of Cancer Recurrence in Patients With High-Risk Early HR+ HER2- Early Breast Cancer

News

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to trial results.

READ MORE

New Genetic System Can Halt or Eliminate Gene Drive in the Wild

News

Scientists at the University of California San Diego and their colleagues have developed two new active genetic systems that address risks associated with gene drives halting or eliminating them in the wild.

READ MORE

Olaparib Successfully Treats Prostate Cancers With Genetic Fault in Clinical Trial

News

Results from the PROfound trial have showed that olaparib – a drug called a PARP inhibitor – can be used successfully to treat prostate cancers with a "weakness" in their ability to repair damaged DNA.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Applied Sciences Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE